Objective To evaluate the clinical efficacy and safety of domestic sparfloxacin in the treatment of acute bacterial infections. Methods A multicenter randomized controlled clinical trial was conducted. 117 patients were treated with domestic sparfloxacin 200-300 mg qd for 5-14 days and 114 patients were treated with domestic lomefloxacin 300 mg bid for 5-14 days. Results The cure rates and the efficacy rates in each group were 84.62%, 74.56% and 94.87%, 92.98%, respectively. The bacterial clearance rates were 94.28% and 92.02%, respectively. Adverse drug reactions rates were 7.69% and 11.40%, most of them were mild. There were no significant differences of above results between the two groups (Pgt;0.05). Conclusions The results suggest that sparfloxacin with wide antibacterial spectrum, satisfactory activity, is an effective and safe antibacterial agent in treatment of mild to moderate acute bacterial infections.
PURPOSE: To investigate the treatment of severe bacterial endophthalmitis. METHODS:The curative effects of vitrectomy after intravitreal antibiotics and steroids (IVAS)for the treatment of 23 patients with bacterial endophthalmitis (group I)and vitrectomy and IVA at the same time for the treatment of 28 patients with bacterial endopbthalmitis (group I)were analyzed retrospectively. RESULTS: The rate of curative effects of two groups were similar,while the marked curative effects in group I (47.8% )was significantly higher than that of the group I (17.9%). The average period of eliminating infiamation of group I was longer than that of group I , and the incidence of postoperative retinal detachment of group Ⅱ was 3 times more than that of group I . CONCLUSION :It was indicated that vitrectomy after IVAS may increase the security of vitrectomy and the curative effects of severe bacterial ndophthalmitis.
Objective To evaluate the efficacy and safety of amoxicillin/sulbactam (AMX/SBT) in the treatment of acute bacterial infections. Method A multicentre randomized controlled clinical trial was conducted. Ampicillin/sulbactam (AMP/SBT) was chosen as the control drug. 113 patients were enrolled in the study (58 cases in test group and 55 cases in control group). AMX/SUL and AMP/SUL were administered 4.5-6.0 g and 4.5-12.0 g every day respectively. Both drugs were given intravenously for 7-14 days. Results The cure rates and the efficacy rates of the two groups were 75.86%, 80.0% and 94.83%, 98.18% respectively. The β-lactamase producing rates were 67.35% , 69.57% and the bacterial clearance rates were 93.88%, 95.65%.There were no significant differences of the above results between the two groups (Pgt;0.05). There was no serious adverse drug reaction in AMX/SBT groups. Conclusion This study suggests that AMX/SBT is an effective and safe drug for treating acute bacterial infections.
ObjectiveTo analyze the prognostic factors of patients with bacterial bloodstream infection sepsis and to identify independent risk factors related to death, so as to potentially develop one predictive model for clinical practice. Method A non-intervention retrospective study was carried out. The relative data of adult sepsis patients with positive bacterial blood culture (including central venous catheter tip culture) within 48 hours after admission were collected from the electronic medical database of the First Affiliated Hospital of Dalian Medical University from January 1, 2018 to December 31, 2019, including demographic characters, vital signs, laboratory data, etc. The patients were divided into a survival group and a death group according to in-hospital outcome. The risk factors were analyzed and the prediction model was established by means of multi-factor logistics regression. The discriminatory ability of the model was shown by area under the receiver operating characteristic curve (AUC). The visualization of the predictive model was drawn by nomogram and the model was also verified by internal validation methods with R language. Results A total of 1189 patients were retrieved, and 563 qualified patients were included in the study, including 398 in the survival group and 165 in the death group. Except gender and pathogen type, other indicators yielded statistical differences in single factor comparison between the survival group and the death group. Independent risk factors included in the logistic regression prediction model were: age [P=0.000, 95% confidence interval (CI) 0.949 - 0.982], heart rate (P=0.000, 95%CI 0.966 - 0.987), platelet count (P=0.009, 95%CI 1.001 - 1.006), fibrinogen (P=0.036, 95%CI 1.010 - 1.325), serum potassium ion (P=0.005, 95%CI 0.426 - 0.861), serum chloride ion (P=0.054, 95%CI 0.939 - 1.001), aspartate aminotransferase (P=0.03, 95%CI 0.996 - 1.000), serum globulin (P=0.025, 95%CI 1.006 - 1.086), and mean arterial pressure (P=0.250, 95%CI 0.995 - 1.021). The AUC of the prediction model was 0.779 (95%CI 0.737 - 0.821). The prediction efficiency of the total score of the model's nomogram was good in the 210 - 320 interval, and mean absolute error was 0.011, mean squared error was 0.00018. Conclusions The basic vital signs within 48 h admitting into hospital, as well those homeostasis disordering index indicated by coagulation, liver and renal dysfunction are highly correlated with the prognosis of septic patients with bacterial bloodstream infection. Early warning should be set in order to achieve early detection and rescue patients’ lives.
ObjectiveTo evaluate the clinical efficacy of Reduning injection combined with antibiotics for infantile bacterial pneumonia. MethodsClinical randomized controlled trials of using Reduning injection combined with antibiotics for infantile bacterial pneumonia retrieved from CNKI Database, VIP Database, and WANFANG Database. RevMan 5.0 software was used for the analysis. ResultsEight studies with 1057 patients were included in the study. The meta-analysis showed no heterogeneity between the studies. In the treatment of infantile pneumonia, Reduning injection combined with antibacterial medicine was significantly better than the control group[OR=4.94, 95% CI (2.99, 8.17), P<0.00001] and had no significant difference compared with the control group in adverse reaction rate[OR=0.83, 95% CI (0.46, 1.51), P=0.55]. ConclusionReduning injection combined with antibacterial medicine is more effective in the treatment of infantile pneumonia than simple antibacterial medicine.
Objective To construct the differential diagnosis model of viral pneumonia and bacterial pneumonia based on lung ultrasonography (LUS) characteristics. Methods A total of 248 patients with pneumonia who completed LUS in our hospital from January 2021 to March 2024 were retrospectively included, and were divided into a viral group (140 cases) and a bacterial group (108 cases) according to the final etiological diagnosis. Predictors in differential diagnosis between viral pneumonia and bacterial pneumonia were analyzed by univariate and multivariate methods. The differential diagnosis model of viral pneumonia and bacterial pneumonia and the prediction efficiency were evaluated. Results Univariate and multivariate logistic analysis showed that the presence or absence of lung consolidation, pleural effusion, B-line range of both lungs and pulmonary ultrasound score were independent predictors of the differential diagnosis of viral pneumonia and bacterial pneumonia (P<0.05). Using the logistic regression model of lung consolidation, pleural effusion, bilateral B-line range, and pulmonary ultrasound score, including the P-values of three variables (lung consolidation, pleural effusion, and bilateral B-line range), and the P-values of four variables (lung consolidation, pleural effusion, bilateral B-line range, and pulmonary ultrasound score), the receiver operating characteristic curve was used to predict the diagnosis of patient. The areas under the curve were 0.863, 0.612, 0.669, 0.684, 0.904, and 0.920, respectively. Conclusion Lung consolidation, pleural effusion, B-line range of both lungs and pulmonary ultrasound score detected by LUS have good diagnostic efficacy in the differential diagnosis of viral pneumonia and bacterial pneumonia, suggesting that LUS technology may be used in the differential diagnosis of viral pneumonia and bacterial pneumonia.
目的总结糖尿病并细菌性肝脓肿(DPHA)的临床特点和诊治经验。方法回顾性分析我院2002年3月至2010年12月期间出院的DPHA与无DPHA(NDPHA)患者的临床资料。结果细菌性肝脓肿患者共22例，其中DPHA患者11例。DPHA组人口学特征、临床表现、白细胞计数与NDPHA组比较差异均无统计学意义(Pgt;0.05); DPHA组血白蛋白低于NDPHA(P=0.006)，而ALT高于NDPHA(P=0.006)。DPHA组病灶个数多于NDPHA组(P=0.032)，且病灶直径也大于NDPHA组(P=0.006)。脓培养: 2组大肠杆菌均为3例; DPHA组克雷伯杆菌4例，而NDPHA组无克雷伯杆菌。DPHA组发生切口感染7例、腹腔感染2例，NDPHA组发生切口感染3例。 DPHA组抗生素使用时间、住院时间及住院费用均高于NDPHA组(Plt;0.05)。2组均分别治愈6例、好转5例，2组均无死亡患者。结论DPHA有其特殊的临床特征，并发症多，住院费用高，但预后与NDPHA差别不大。